Bitcoin price today: surges to $122k, near record high on US regulatory cheer
Director Kim R. Tsuchimoto of Monopar Therapeutics (NASDAQ:MNPR), sold 8,904 shares of common stock on July 14, 2025. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, netting approximately $356,170. The transaction comes as MNPR shares have surged over 1,000% in the past year, with the stock currently trading at $41.07. According to InvestingPro, the company maintains a GOOD financial health score.
On the same day, Tsuchimoto also acquired 8,904 shares of Monopar Therapeutics common stock, with a total value of $44.
Additionally, Ms. Tsuchimoto exercised options to purchase 4,200 shares granted on April 4, 2016, and 4,704 shares granted on February 20, 2017.
In other recent news, Monopar Therapeutics has been added to the Russell 3000 and Russell 2000 indexes, highlighting its growth and development of the late-stage drug candidate ALXN1840 for Wilson disease. This inclusion is seen as a recognition of the company’s progress and is effective for one year until the next reconstitution. FTSE Russell, which provides these indexes, is a global leader in index and data solutions, with around $10.6 trillion in assets benchmarked against them as of May 2025. Additionally, Chardan Capital Markets initiated coverage on Monopar with a buy rating, citing the potential of its Wilson disease treatment and radiopharmaceutical pipeline. The ALXN1840 drug, acquired from AstraZeneca (NASDAQ:AZN)’s subsidiary, demonstrated significant efficacy in its phase III trial, achieving primary endpoints. Despite AstraZeneca previously terminating its development due to concerns, Monopar plans to seek FDA approval in early 2026. The company is also focused on developing novel radiopharmaceuticals for enhanced imaging and therapeutic applications. Monopar has indicated plans to continue raising funds to support its clinical, regulatory, and commercial efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.